Cardiff Oncology, Inc. (NASDAQ:CRDF) Stock Now Rated “Hold” by Wall Street Brokerages

Cardiff Oncology, Inc. (NASDAQ:CRDF) has been given an average rating of “Hold” by the seven analysts that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, three have given a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $7.50.

Several equities research analysts recently issued reports on the company. HC Wainwright raised Cardiff Oncology from a “neutral” rating to a “buy” rating in a research note on Tuesday, September 15th. Weiss Ratings upgraded Cardiff Oncology from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday. William Blair cut Cardiff Oncology from an “outperform” rating to a “market perform” rating in a report on Tuesday, August 11th. Finally, Wall Street Zen upgraded Cardiff Oncology from a “strong sell” rating to a “sell” rating in a research report on Saturday, September 5th.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. BlackRock Inc. bought a new position in shares of Cardiff Oncology in the 2nd quarter worth $1,265,000. GoalVest Advisory LLC purchased a new stake in shares of Cardiff Oncology during the 3rd quarter valued at $832,000. Flputnam Investment Management Co. purchased a new stake in shares of Cardiff Oncology during the 2nd quarter valued at $322,000. X Square Capital LLC purchased a new stake in shares of Cardiff Oncology during the 2nd quarter valued at $267,000. Finally, GSA Capital Partners LLP bought a new stake in shares of Cardiff Oncology during the 2nd quarter worth $225,000. 16.29% of the stock is currently owned by institutional investors.

Cardiff Oncology Price Performance

NASDAQ:CRDF traded down $0.03 during trading hours on Tuesday, hitting $1.01. The stock had a trading volume of 82,495 shares, compared to its average volume of 1,096,817. The company has a 50 day simple moving average of $1.09 and a two-hundred day simple moving average of $1.32. The firm has a market capitalization of $78.57 million, a price-to-earnings ratio of -1.68 and a beta of 1.42. Cardiff Oncology has a one year low of $0.76 and a one year high of $3.31.

Cardiff Oncology (NASDAQ:CRDF) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.02). Cardiff Oncology had a negative return on equity of 103.10% and a negative net margin of 7,885.43%. The firm had revenue of $0.10 million during the quarter, compared to the consensus estimate of $0.06 million. Equities research analysts anticipate that Cardiff Oncology will post -0.60 earnings per share for the current year.

About Cardiff Oncology

Cardiff Oncology, Inc is a clinical-stage biotechnology company focused on developing cancer therapies designed to target difficult-to-treat tumors. The company’s lead investigational product is onvansertib, an oral, highly selective inhibitor of polo-like kinase 1 (PLK1), a protein involved in cell division and tumor growth.

Cardiff Oncology has primarily evaluated onvansertib in combination with existing treatments for patients with RAS-mutated metastatic colorectal cancer, including regimens involving chemotherapy and targeted agents.